Literature DB >> 2322567

The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes.

S Yamano1, J Tatsuno, F J Gonzalez.   

Abstract

Three cDNAs, designated IIA3, IIA3v, and IIA4, coding for P450s in the CYP2A gene subfamily were isolated from a lambda gt11 library prepared from human hepatic mRNA. Only three nucleotide differences and a single amino acid difference, Leu160----His, were found between IIA3 and IIA3v, indicating that they are probably allelic variants. IIA4 displayed 94% amino acid similarity with IIA3 and IIA3v. The three cDNAs were inserted into vaccinia virus, and recombinant viruses were used to infect human hepatoma Hep G2 cells. Only IIA3 was able to produce an enzyme that had a reduced CO-bound spectrum with a lambda max at 450 nm. This expressed enzyme was able to carry out coumarin 7-hydroxylation (turnover number of 15 min-1) and ethoxycoumarin O-deethylation. cDNA-expressed IIA3v and IIA4 failed to incorporate heme and were enzymatically inactive. Analysis of IIA proteins in human liver microsomes, using antibody against rat IIA2, revealed two proteins of 49 and 50 kDa, the former of which appeared to correlate with human microsomal coumarin 7-hydroxylase activity. A more striking correlation was found between IIA mRNA and enzyme activity. The rat antibody was able to completely abolish coumarin 7-hydroxylase activity in 12 liver samples. In addition, kinetics of coumarin metabolism in two livers were monophasic over the substrate concentration tested. Km values obtained from human liver (2.3 microM) were similar to those obtained from lysates of hepatoma cells expressing IIA3 (3.6-7.1 microM).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322567     DOI: 10.1021/bi00457a031

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  52 in total

Review 1.  Polymorphisms of CYP2A6 and its practical consequences.

Authors:  H Raunio; A Rautio; H Gullstén; O Pelkonen
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

2.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.

Authors:  Ryoko Yoshida; Miki Nakajima; Yuki Watanabe; Jun-Tack Kwon; Tsuyoshi Yokoi
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

3.  CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.

Authors:  Catherine A Wassenaar; Qian Zhou; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2015-12-15       Impact factor: 2.533

4.  CYP2A6 genetic variation and dexmedetomidine disposition.

Authors:  Utkarsh Kohli; Pratik Pandharipande; Mordechai Muszkat; Gbenga G Sofowora; Eitan A Friedman; Mika Scheinin; Alastair J J Wood; E Wesley Ely; Rachel F Tyndale; Leena Choi; C Michael Stein; Daniel Kurnik
Journal:  Eur J Clin Pharmacol       Date:  2012-01-21       Impact factor: 2.953

5.  CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling.

Authors:  Samuel L Collom; Arvind P Jamakhandi; Alan J Tackett; Anna Radominska-Pandya; Grover P Miller
Journal:  Arch Biochem Biophys       Date:  2006-11-02       Impact factor: 4.013

Review 6.  Nicotinic receptors containing the alpha7 subunit: a model for rational drug design.

Authors:  G Sharma; S Vijayaraghavan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Interindividual variability of coumarin 7-hydroxylation in a Turkish population.

Authors:  M Iscan; H Rostami; M Iscan; T Güray; O Pelkonen; A Rautio
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers.

Authors:  U Merkel; H Sigusch; A Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Association of CYP2A6 deletion polymorphism with smoking habit and development of pulmonary emphysema.

Authors:  N Minematsu; H Nakamura; M Iwata; H Tateno; T Nakajima; S Takahashi; S Fujishima; K Yamaguchi
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

10.  Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors.

Authors:  Nael Al Koudsi; Ewa B Hoffmann; Abbas Assadzadeh; Rachel F Tyndale
Journal:  Eur J Clin Pharmacol       Date:  2009-12-09       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.